The Co-CEOs of Amylyx discuss Wednesday's news that they have acquired a GLP-1 antagonist as a new pipeline asset

blonca9
Jul 12, 2024
1 min read

Josh Cohen and Justin Klee explain why they chose this program, and what the potential timeline looks like for a phase 3 trial. Plus, an update on Amylyx's existing pipeline, including recent data in Wolfram Syndrome.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

The Co-CEOs of Amylyx discuss Wednesday's news that they have acquired a GLP-1 antagonist as a new pipeline asset

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight